Eli Lilly invests USD126M to expand Kobe plant for obesity drugs in Japan

JAPAN—Eli Lilly continues expanding its manufacturing footprint beyond the United States, announcing a 20 billion yen (USD 126 million) investment in its Seishin plant located in Kobe, Japan.

The pharmaceutical giant plans to install a new production line and construct an additional warehouse at the facility by 2028, according to a company press release on March 12.

The expansion will focus on manufacturing diabetes and obesity medications, Nikkei Asia reported on March 12.

While Lilly hasn’t officially confirmed which specific drugs will benefit from the upgraded capacity, the company manufactures tirzepatide, a dual GIP/GLP-1 medication marketed for both diabetes and obesity, in partnership with local collaborator Mitsubishi Tanabe.

Responding to rising demand

The Seishin facility, established in 1981, currently employs approximately 315 workers and serves as Lilly’s only in-house production site in Japan.

The plant spans 23,000 square meters (247,570 square feet) and primarily handles analytical testing, inspection, and packaging of Lilly products.

Lilly emphasized that the investment addresses “increasing demand” in the Japanese market, noting the importance of responding “quickly and flexibly to future supply expansions.”

The company also plans to advance digitalization and process optimization at the plant to better serve local customers.

This latest commitment builds on a previous 7 billion yen (USD44 million) investment between 2022 and 2025, which funded automated device-sorting machines, enhancements to the quality testing lab, a new factory building, and an additional packaging line.

Part of broader Asian expansion strategy

The Japan announcement follows Lilly’s revelation earlier this week of a massive USD 3 billion investment in Chinese manufacturing operations.

The decade-long project will establish local production of oral solid medications, particularly orforglipron, the company’s GLP-1 pill for obesity, which is currently under regulatory review globally.

Lilly will collaborate with multiple Chinese manufacturing partners, starting with Beijing-based contract development and manufacturing organization Pharmaron.

Additionally, Lilly recently pledged USD500 million to South Korea, though this investment targets clinical trial recruitment and the establishment of a Lilly Gateway Labs incubator rather than manufacturing infrastructure.

Balancing global and domestic manufacturing

Despite these international expansions, Lilly maintains a strong commitment to United States-based production.

The company recently announced plans for a USD3.5 billion injectables and device facility in Pennsylvania, adding to previously announced manufacturing sites in Virginia, Texas, and Alabama.

These domestic investments align with broader pharmaceutical industry efforts to strengthen American manufacturing amid potential import tariff policies from the Trump administration.

However, Lilly’s simultaneous overseas expansions demonstrate the company’s strategy of building manufacturing capacity close to key markets worldwide, particularly as demand for obesity and diabetes treatments continues to surge across multiple regions.